E
AACR MT Boston

Update on overcoming resistance in metastatic melanoma

What new clinical approaches are being investigated to overcome resistance in melanoma?

March 20, 2014
E
aacr molecular targets boston 2013

The future of cancer research – Part 2

The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...

November 6, 2013
E
Iwakuni Bridge

The future of cancer research – what I learned from the AACR Targets meeting Part 1

The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.

November 5, 2013
E
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013
E
Fall Colors Boston

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E
Fall Boston Colors

Abraxane kills potential of MLN0264 in pancreatic cancer

Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.

October 21, 2013
E
Boston Prudential Center

Cerulean CRLX101 Challenges and Opportunities

Cerulean are developing a novel nanopharmaceutical that targets HIF1-alpha and is synergistic with anti-angiogenic drugs for RCC and Ovarian cancers.

October 21, 2013
E
Charles River Boston October 2013

AstraZeneca ramps up AZD9291 lung cancer clinical development

At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.

October 20, 2013
E
Boston Charles River October 2013

Pfizer next gen ALK inhibitor PF-06463922 could replace Xalkori

Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.

October 20, 2013
E
MIT Koch

A quick preview of the AACR Molecular Targets Conference

Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston

October 15, 2013
E
Back Bay Boston

Preview of 2013 AACR Molecular Targets Conference in Boston

Preview of 2013 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston. This is a "must attend" meeting for anyone interested in cancer drug development.

October 11, 2013
E
CDK4/6 inhibition - Source: Lilly

CDK inhibitors: will palbociclib and LEE011 make it to market in breast cancer?

Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.

March 19, 2014